Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 130.1 kDa. The protein migrates as 65-80 kDa,95-120 kDa and 160-180 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Mouse IGF-I R Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Mouse IGF-I R Protein, Fc Tag (Cat. No. IGR-M5253) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGF-I, Avitag,Fc Tag (Cat. No. IG1-H82F7) with a linear range of 0.039-1.25 μg/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Dwarfism; Diabetes Mellitus, Lipoatrophic; Growth hormone deficiency | null | 1994-10-05 | HIV Infections; Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; Lipodystrophy; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | IGF-1; FK-780; MKN-031 | Approved | Ipsen | Increlex | EU | Laron Syndrome | Ipsen Pharma | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; X-Linked Combined Immunodeficiency Diseases; Phelan-McDermid syndrome; Growth Disorders; Muscular Dystrophy, Duchenne; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad, Takeda Pharmaceutical Co Ltd | Alunbrig | Mainland China | Carcinoma, Non-Small-Cell Lung | Takeda (China) International Trading Co Ltd | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Meningioma; Neurilemmoma; Neuroma, Acoustic | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001 | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Sarcoma; Breast Neoplasms; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | Mainland China | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Hepatic Insufficiency; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Thyroid Carcinoma, Anaplastic; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Stomach Neoplasms | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Sunburn | Details | |
Lonigutamab | VB-421 | Phase 1 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
BVS-857 | BVS-857 | Novartis Pharma Ag | Details | ||
VPI-2690B | VPI-2690B | University Of North Carolina At Chapel Hill | Details | ||
KW-2450 | KW-2450 | Kyowa Hakko Kirin Co Ltd | Details | ||
BIIB-022 | BIIB-022 | Biogen Inc | Details | ||
Mecasermin Rinfabate | OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Myotonic Dystrophy; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Muscular Dystrophies; Laron Syndrome | Details |
Teprotumumab biosimilar(Innovent) | IBI-311 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Graves Ophthalmopathy | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Endocrine System Diseases; Paraganglioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Eye Diseases; Orbital Diseases; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma, Ewing; Graves Ophthalmopathy; Solid tumours; Multiple Myeloma; Adrenocortical Carcinoma; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Skin Neoplasms; Neoplasms; Hashimoto Disease; Carney Complex; Liver Neoplasms; Chondrosarcoma; Thyroid Diseases; Ovarian Neoplasms | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Osteosarcoma; Gliosarcoma; Adenocarcinoma, Bronchiolo-Alveolar; Colorectal Neoplasms; Medullary thyroid cancer (MTC); Neuroblastoma; Gastrinoma; Neurofibrosarcoma; Retinoblastoma; Brain Stem Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Liposarcoma; Glucagonoma; Esophageal adenocarcinoma; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Paraganglioma; Melanoma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Sarcoma, Alveolar Soft Part; Adrenocortical Carcinoma; Glioma; Rhabdomyosarcoma, Alveolar; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Carcinoma, Neuroendocrine; Lung Neoplasms; Pinealoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Insulinoma; Hemangiosarcoma; Mesenchymoma; Hepatoblastoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Desmoplastic Small Round Cell Tumor; Kidney Neoplasms; Fibrosarcoma; Chondrosarcoma; Liver Neoplasms; Head and Neck Neoplasms; Leiomy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Prostatic Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Gastrointestinal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Rhabdomyosarcoma, Alveolar; Lymphoma; Lung Neoplasms; Neuroectodermal Tumors, Primitive; Colorectal Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Sarcoma; Solid tumours; Pancreatic Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Rhabdomyosarcoma, Embryonal; Rectal Neoplasms; Carcinoid Tumor; Ovarian Neoplasms; Rhabdomyosarcoma; Bone metastases; Intestinal Neoplasms | Details |
Humanized IgG1κ monoclonal antibody(Viridian) | ZB-001; AVE-1642; VRDN-001 | Phase 2 Clinical | Viridian Therapeutics Inc | Solid tumours; Multiple Myeloma; Graves Ophthalmopathy; Breast Neoplasms | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Uveal melanoma; Adrenocortical Carcinoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
PHP-1003 | PHP-1003; PHP1003 | Phase 1 Clinical | Graves Ophthalmopathy | Details | |
lonigutamab ugodotin | W-0101 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours | Details |
Conteltinib | CT-707; SY-707 | Phase 3 Clinical | Shouyao Holding (Beijing) Co Ltd, Centaurus Biopharma Co Ltd | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.